1
|
Pavelec CM, Young AP, Luviano HL, Orrell EE, Szagdaj A, Poudel N, Wolpe AG, Thomas SH, Yeudall S, Upchurch CM, Okusa MD, Isakson BE, Wolf MJ, Leitinger N. Cardiomyocyte PANX1 Controls Glycolysis and Neutrophil Recruitment in Hypertrophy. Circ Res 2024; 135:503-517. [PMID: 38957990 PMCID: PMC11293983 DOI: 10.1161/circresaha.124.324650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Accepted: 06/21/2024] [Indexed: 07/04/2024]
Abstract
BACKGROUND PANX1 (pannexin 1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation, blood pressure regulation, and myocardial infarction. However, the possible role of PANX1 in cardiomyocytes in the progression of heart failure has not yet been investigated. METHOD We generated a novel mouse line with constitutive deletion of PANX1 in cardiomyocytes (Panx1MyHC6). RESULTS PANX1 deletion in cardiomyocytes had no effect on unstressed heart function but increased the glycolytic metabolism and resulting glycolytic ATP production, with a concurrent decrease in oxidative phosphorylation, both in vivo and in vitro. In vitro, treatment of H9c2 (H9c2 rat myoblast cell line) cardiomyocytes with isoproterenol led to PANX1-dependent release of ATP and Yo-Pro-1 uptake, as assessed by pharmacological blockade with spironolactone and siRNA-mediated knockdown of PANX1. To investigate nonischemic heart failure and the preceding cardiac hypertrophy, we administered isoproterenol, and we demonstrated that Panx1MyHC6 mice were protected from systolic and diastolic left ventricle volume increases as a result of cardiomyocyte hypertrophy. Moreover, we found that Panx1MyHC6 mice showed decreased isoproterenol-induced recruitment of immune cells (CD45+), particularly neutrophils (CD11b+ [integrin subunit alpha M], Ly6g+ [lymphocyte antigen 6 family member G]), to the myocardium. CONCLUSIONS Together, these data demonstrate that PANX1 deficiency in cardiomyocytes increases glycolytic metabolism and protects against cardiac hypertrophy in nonischemic heart failure at least in part by reducing immune cell recruitment. Our study implies PANX1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in patients with heart failure.
Collapse
Affiliation(s)
- Caitlin M Pavelec
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
- Robert M. Berne Cardiovascular Research Center (C.M.P., A.P.Y., B.E.I., M.J.W., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Alexander P Young
- Cardiovascular Medicine, Department of Medicine (A.P.Y., M.J.W.), University of Virginia School of Medicine, Charlottesville
- Robert M. Berne Cardiovascular Research Center (C.M.P., A.P.Y., B.E.I., M.J.W., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Hannah L Luviano
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Emily E Orrell
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Anna Szagdaj
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Nabin Poudel
- Division of Nephrology and Center for Immunity, Inflammation and Regenerative Medicine (N.P., M.D.O.), University of Virginia School of Medicine, Charlottesville
| | - Abigail G Wolpe
- Department of Cell Biology (A.G.W.), University of Virginia School of Medicine, Charlottesville
| | - Samantha H Thomas
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Scott Yeudall
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Clint M Upchurch
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Mark D Okusa
- Division of Nephrology and Center for Immunity, Inflammation and Regenerative Medicine (N.P., M.D.O.), University of Virginia School of Medicine, Charlottesville
| | - Brant E Isakson
- Robert M. Berne Cardiovascular Research Center (C.M.P., A.P.Y., B.E.I., M.J.W., N.L.), University of Virginia School of Medicine, Charlottesville
- Department of Molecular Physiology and Biological Physics (B.E.I.), University of Virginia School of Medicine, Charlottesville
| | - Matthew J Wolf
- Cardiovascular Medicine, Department of Medicine (A.P.Y., M.J.W.), University of Virginia School of Medicine, Charlottesville
- Robert M. Berne Cardiovascular Research Center (C.M.P., A.P.Y., B.E.I., M.J.W., N.L.), University of Virginia School of Medicine, Charlottesville
| | - Norbert Leitinger
- Department of Pharmacology (C.M.P., H.L.L., E.E.O., A.S., S.H.T., S.Y., C.M.U., N.L.), University of Virginia School of Medicine, Charlottesville
- Robert M. Berne Cardiovascular Research Center (C.M.P., A.P.Y., B.E.I., M.J.W., N.L.), University of Virginia School of Medicine, Charlottesville
| |
Collapse
|
2
|
Pavelec CM, Young AP, Luviano HL, Orrell EE, Szagdaj A, Poudel N, Wolpe AG, Thomas SH, Yeudall S, Upchurch CM, Okusa MD, Isakson BE, Wolf MJ, Leitinger N. Pannexin 1 Channels Control Cardiomyocyte Metabolism and Neutrophil Recruitment During Non-Ischemic Heart Failure. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2023.12.29.573679. [PMID: 38234768 PMCID: PMC10793433 DOI: 10.1101/2023.12.29.573679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Abstract
Pannexin 1 (PANX1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation, blood pressure regulation, and myocardial infarction. However, a possible role of PANX1 in cardiomyocytes in the progression of heart failure has not yet been investigated. We generated a novel mouse line with constitutive deletion of PANX1 in cardiomyocytes (Panx1 MyHC6 ). PANX1 deletion in cardiomyocytes had no effect on unstressed heart function but increased the glycolytic metabolism both in vivo and in vitro . In vitro , treatment of H9c2 cardiomyocytes with isoproterenol led to PANX1-dependent release of ATP and Yo-Pro-1 uptake, as assessed by pharmacological blockade with spironolactone and siRNA-mediated knock-down of PANX1. To investigate non-ischemic heart failure and the preceding cardiac hypertrophy we administered isoproterenol, and we demonstrate that Panx1 MyHC6 mice were protected from systolic and diastolic left ventricle volume increases and cardiomyocyte hypertrophy. Moreover, we found that Panx1 MyHC6 mice showed decreased isoproterenol-induced recruitment of immune cells (CD45 + ), particularly neutrophils (CD11b + , Ly6g + ), to the myocardium. Together these data demonstrate that PANX1 deficiency in cardiomyocytes impacts glycolytic metabolism and protects against cardiac hypertrophy in non-ischemic heart failure at least in part by reducing immune cell recruitment. Our study implies PANX1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in heart failure patients.
Collapse
|
3
|
Guo AH, Baliira R, Skinner ME, Kumar S, Andren A, Zhang L, Goldsmith RS, Michan S, Davis NJ, Maccani MW, Day SM, Sinclair DA, Brody MJ, Lyssiotis CA, Stein AB, Lombard DB. Sirtuin 5 levels are limiting in preserving cardiac function and suppressing fibrosis in response to pressure overload. Sci Rep 2022; 12:12258. [PMID: 35851833 PMCID: PMC9293976 DOI: 10.1038/s41598-022-16506-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 07/11/2022] [Indexed: 11/08/2022] Open
Abstract
Heart failure (HF) is the inability of the heart to pump blood sufficiently to meet the metabolic demands of the body. HF with reduced systolic function is characterized by cardiac hypertrophy, ventricular fibrosis and remodeling, and decreased cardiac contractility, leading to cardiac functional impairment and death. Transverse aortic constriction (TAC) is a well-established model for inducing hypertrophy and HF in rodents. Mice globally deficient in sirtuin 5 (SIRT5), a NAD+-dependent deacylase, are hypersensitive to cardiac stress and display increased mortality after TAC. Prior studies assessing SIRT5 functions in the heart have all employed loss-of-function approaches. In this study, we generated SIRT5 overexpressing (SIRT5OE) mice, and evaluated their response to chronic pressure overload using TAC. Compared to littermate controls, SIRT5OE mice were protected against adverse functional consequences of TAC, left ventricular dilation and impaired ejection fraction. Transcriptomic analysis revealed that SIRT5 suppresses key HF sequelae, including the metabolic switch from fatty acid oxidation to glycolysis, immune activation, and fibrotic signaling pathways. We conclude that SIRT5 is a limiting factor in the preservation of cardiac function in response to experimental pressure overload.
Collapse
Affiliation(s)
- Angela H Guo
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
- Molecular and Cellular Pathology Graduate Program, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Rachael Baliira
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Mary E Skinner
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Surinder Kumar
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Anthony Andren
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Li Zhang
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Robert S Goldsmith
- Department of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA
- Pharmacology Graduate Program, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Shaday Michan
- Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA
- Rejuvenate Bio Inc, San Diego, CA, 92121, USA
| | - Norma J Davis
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Merissa W Maccani
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Sharlene M Day
- Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
| | - David A Sinclair
- Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA
| | - Matthew J Brody
- Department of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Costas A Lyssiotis
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA
| | - Adam B Stein
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
| | - David B Lombard
- Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.
- Institute of Gerontology, University of Michigan, Ann Arbor, MI, 48109, USA.
- Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, 708 Biomedical Research Building, 1501 NW 10th Avenue, Miami, FL, 33136, USA.
- Sylvester Comprehensive Cancer Center, Miami, FL, 33136, USA.
| |
Collapse
|
4
|
Sanjeewa KKA, Herath KHINM, Yang HW, Choi CS, Jeon YJ. Anti-Inflammatory Mechanisms of Fucoidans to Treat Inflammatory Diseases: A Review. Mar Drugs 2021; 19:678. [PMID: 34940677 PMCID: PMC8703547 DOI: 10.3390/md19120678] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 11/22/2021] [Accepted: 11/25/2021] [Indexed: 12/12/2022] Open
Abstract
Fucoidans are sulfated heteropolysaccharides found in the cell walls of brown seaweeds (Phaeophyceae) and in some marine invertebrates. Generally, fucoidans are composed of significant amounts of L-fucose and sulfate groups, and lesser amounts of arabinose, galactose, glucose, glucuronic acid, mannose, rhamnose, and xylose. In recent years, fucoidans isolated from brown seaweeds have gained considerable attention owing to their promising bioactive properties such as antioxidant, immunomodulatory, anti-inflammatory, antiobesity, antidiabetic, and anticancer properties. Inflammation is a complex immune response that protects the organs from infection and tissue injury. While controlled inflammatory responses are beneficial to the host, leading to the removal of immunostimulants from the host tissues and restoration of structural and physiological functions in the host tissues, chronic inflammatory responses are often associated with the pathogenesis of tumor development, arthritis, cardiovascular diseases, diabetes, obesity, and neurodegenerative diseases. In this review, the authors mainly discuss the studies since 2016 that have reported anti-inflammatory properties of fucoidans isolated from various brown seaweeds, and their potential as a novel functional material for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- Kalu K. Asanka Sanjeewa
- Department of Biosystems Technology, Faculty of Technology, University of Sri Jayewardenepura, Pittpana, Homagoma 10200, Sri Lanka;
| | - Kalahe H. I. N. M. Herath
- Department of Biosystems Engineering, Faculty of Agriculture and Plantation Management, Wayamba University of Sri Lanka, Makandura, Gonawila 60170, Sri Lanka;
| | - Hye-Won Yang
- Department of Marine Life Science, Jeju National University, Jeju 63243, Korea;
| | - Cheol Soo Choi
- Korea Mouse Metabolic Phenotyping Center, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Korea
| | - You-Jin Jeon
- Department of Marine Life Science, Jeju National University, Jeju 63243, Korea;
- Marine Science Institute, Jeju National University, Jeju 63333, Korea
| |
Collapse
|